Literature DB >> 8252205

Epidermal growth factor receptor expression in squamous cell carcinoma of the hypopharynx.

J L Frank1, J L Garb, B B Banson, J Peterman, J P Neifeld, S Kay, M J Kornstein, A Sismanis, J L Ware.   

Abstract

Expression of the epidermal growth factor receptor (EGFR) has been demonstrated in normal and malignant squamous epithelia. Its presence has been suggested to be important in the pathophysiology and prognosis of epithelial cancers. Archival tumour specimens from 57 patients with squamous cell carcinoma of the hypopharynx were studied using OM-11-951, a new murine anti-EGFR monoclonal antibody which recognizes the receptor on deparaffinized tissue. By visual inspection, 28 (49%) tumours were EGFR negative; 29 (51%) tumours were EGFR positive. While patients whose tumours were EGFR positive were younger, there was no significant correlation with other clinical or pathological variables (including grade and stage). Patients whose tumours were EGFR negative had a median survival of 21 (95% CI 4.3-37.7) months compared with a median survival of 17 (95% CI 11.4-22) months for patients whose tumours were EGFR positive. The difference was not statistically significant. A multiple regression analysis did not demonstrate EGFR status to be important in predicting survival. These data cast doubt on the prognostic significance of EGFR expression in this neoplasm.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252205     DOI: 10.1016/0960-7404(93)90003-h

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  2 in total

Review 1.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

2.  miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC).

Authors:  N Kikkawa; T Hanazawa; L Fujimura; N Nohata; H Suzuki; H Chazono; D Sakurai; S Horiguchi; Y Okamoto; N Seki
Journal:  Br J Cancer       Date:  2010-08-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.